

# The management of ascites in cirrhosis: Report on the c International Ascites Club

Hepatology

38, 258-266

DOI: [10.1053/jhep.2003.50315](https://doi.org/10.1053/jhep.2003.50315)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Treatment of ascites. Current Treatment Options in Gastroenterology, 2003, 6, 481-491.	0.3	13
2	Nitrous Oxide Attenuates Pressor but Augments Norepinephrine Response to Laryngoscopy and Endotracheal Intubation. Anesthesia and Analgesia, 2003, 96, 1516-1521.	1.1	5
3	Covered transjugular intrahepatic portosystemic stents maintain lower portal pressure and require fewer reinterventions than uncovered stents. Scandinavian Journal of Gastroenterology, 2004, 39, 994-999.	0.6	13
4	Evidence-based Colloid Use in the Critically Ill. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1247-1259.	2.5	169
5	Management of refractory ascites. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, S194-S199.	1.4	3
6	Hepatic hydrothorax. Alimentary Pharmacology and Therapeutics, 2004, 20, 271-279.	1.9	127
7	Prognosis of hepatorenal syndrome - has it changed with current practice?. Alimentary Pharmacology and Therapeutics, 2004, 20, 44-46.	1.9	17
8	Hepatorenal syndrome - how to assess response to treatment and nonpharmacological therapy. Alimentary Pharmacology and Therapeutics, 2004, 20, 49-54.	1.9	10
9	Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver International, 2004, 24, 457-464.	1.9	117
13	Performance standards for therapeutic abdominal paracentesis. Hepatology, 2004, 40, 484-488.	3.6	246
16	Discussion on the North American study for the treatment of refractory ascites. Gastroenterology, 2004, 126, 1214-1215.	0.6	2
18	Hepatorenal syndrome: pathogenesis and novel pharmacological targets. Current Opinion in Pharmacology, 2004, 4, 189-197.	1.7	10
19	Ascitis y s?ndrome hepatorenal. Medicina, 2004, 9, 504-512.	0.0	0
20	TIPS Versus Peritoneovenous Shunt in the Treatment of Medically Intractable Ascites. Annals of Surgery, 2004, 239, 883-891.	2.1	66
21	Ascites and intraabdominal infection. Current Opinion in Critical Care, 2004, 10, 146-151.	1.6	8
22	TIPS versus paracentesis for cirrhotic patients with refractory ascites. , 2004, , CD004889.		29
23	Nitric oxide and renal function in cirrhotic patients with ascites. European Journal of Gastroenterology and Hepatology, 2004, 16, 567-570.	0.8	20
24	Preoperative optimization of patients with liver disease. Current Opinion in Anaesthesiology, 2005, 18, 325-331.	0.9	8

#	ARTICLE	IF	CITATIONS
25	Transjugular intrahepatic portosystemic stent shunt: 11 years?? experience at a regional referral centre. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 1165-1171.	0.8	18
26	A puzzling complication of liver disease. <i>Nursing Made Incredibly Easy</i> , 2005, 3, 54-56.	0.2	0
27	Liver transplantation in patients with hepatic hydrothorax. <i>Transplant International</i> , 2005, 18, 672-675.	0.8	79
28	Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 525-529.	1.9	165
29	Usefulness of routine analysis of ascitic fluid at the time of therapeutic paracentesis in asymptomatic outpatients. <i>Gastroenterologie Clinique Et Biologique</i> , 2005, 29, 275-279.	0.9	32
30	Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. <i>Liver Transplantation</i> , 2005, 11, 336-343.	1.3	375
31	Chronic Albumin Infusions to Achieve Diuresis in Patients with Ascites Who Are Not Candidates for Transjugular Intrahepatic Portosystemic Shunt (TIPS). <i>Digestive Diseases and Sciences</i> , 2005, 50, 1356-1360.	1.1	17
32	Ovarian carcinoma in two patients with chronic liver disease. <i>World Journal of Gastroenterology</i> , 2005, 11, 4445.	1.4	1
33	Transjugular Intrahepatic Portosystemic Shunt in the Management of Refractory Ascites. <i>Seminars in Interventional Radiology</i> , 2005, 22, 278-286.	0.3	17
34	Adhesion molecules as a prognostic marker of liver cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 217-224.	0.6	37
35	Refractory Ascites. <i>Digestive Diseases</i> , 2005, 23, 30-38.	0.8	31
36	Hepatorenal Syndrome. <i>Digestive Diseases</i> , 2005, 23, 47-55.	0.8	32
37	Transjugular Intrahepatic Portosystemic Shunt. <i>Digestive Diseases</i> , 2005, 23, 56-64.	0.8	46
38	Hemostatic Defects in End Stage Liver Disease. <i>Critical Care Clinics</i> , 2005, 21, 563-587.	1.0	90
39	Management of Refractory Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 1187-1191.	2.4	32
40	Management of complications of cirrhosis in patients awaiting liver transplantation. <i>Journal of Hepatology</i> , 2005, 42, S124-S133.	1.8	56
41	A novel sodium overload test predicting ascites decompensation in rats with CCl4-induced cirrhosis. <i>Journal of Hepatology</i> , 2005, 43, 92-97.	1.8	14
42	Ascites from cirrhotic patients induces angiogenesis through the phosphoinositide 3-kinase/Akt signaling pathway. <i>Journal of Hepatology</i> , 2005, 43, 85-91.	1.8	13

#	ARTICLE	IF	CITATIONS
43	The aldosterone antagonist and facultative diuretic eplerenone: a critical review. <i>European Journal of Internal Medicine</i> , 2005, 16, 3-11.	1.0	26
44	The aldosterone antagonist and facultative diuretic eplerenone: A critical review. <i>European Journal of Internal Medicine</i> , 2005, 16, 145-153.	1.0	0
45	Syndrom h�pator�nal. <i>EMC - Nephrologie</i> , 2005, 2, 1-7.	0.0	0
46	Should bleeding tendency deter abdominal paracentesis?. <i>Digestive and Liver Disease</i> , 2005, 37, 946-951.	0.4	57
47	Management of Ascites in Cirrhosis. <i>Clinics in Liver Disease</i> , 2005, 9, 715-732.	1.0	45
48	New Management Options for End-Stage Chronic Liver Disease and Acute Liver Failure. <i>Paediatric Drugs</i> , 2006, 8, 1-13.	1.3	31
49	Current management of the complications of portal hypertension: variceal bleeding and ascites. <i>Cmaj</i> , 2006, 174, 1433-1443.	0.9	55
50	The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2006, 3, 380-389.	1.7	25
51	Guidelines on the management of ascites in cirrhosis. <i>Gut</i> , 2006, 55, vi1-vi12.	6.1	270
52	Effect of Potassium Canrenoate, an Anti-aldosterone Agent, on Incidence of Ascites and Variceal Progression in Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1395-1402.	2.4	10
53	Palliation of Malignant Ascites. <i>Gastroenterology Clinics of North America</i> , 2006, 35, 189-199.	1.0	52
54	Hyponatremia Impairs Early Posttransplantation Outcome in Patients With Cirrhosis Undergoing Liver Transplantation. <i>Gastroenterology</i> , 2006, 130, 1135-1143.	0.6	179
55	TIPS versus paracentesis for cirrhotic patients with refractory ascites. <i>The Cochrane Library</i> , 2006, , CD004889.	1.5	99
56	Natural History of Patients Hospitalized for Management of Cirrhotic Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1385-1394.e1.	2.4	352
57	Long-term albumin infusion improves survival in patients with cirrhosis and ascites: An unblinded randomized trial. <i>World Journal of Gastroenterology</i> , 2006, 12, 1403.	1.4	128
58	The use of TIPS in chronic liver disease. <i>Annals of Hepatology</i> , 2006, 5, 5-15.	0.6	40
59	Colloidal and Pharmacological Activity of Albumin in Clinical Fluid Management:Recent Developments. <i>Current Drug Therapy</i> , 2006, 1, 319-328.	0.2	2
60	Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1143-1150.	0.8	12

#	ARTICLE	IF	CITATIONS
61	Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival?. <i>Transplant International</i> , 2006, 19, 275-281.	0.8	49
62	Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 75-84.	1.9	70
63	Treatment of refractory ascites. <i>Current Treatment Options in Gastroenterology</i> , 2006, 9, 530-537.	0.3	7
64	Refractory Ascites After Liver Transplantation: An Analysis of 1058 Liver Transplant Patients at a Single Center. <i>American Journal of Transplantation</i> , 2006, 6, 140-149.	2.6	42
65	The use of vasoconstrictors in patients with cirrhosis: Type 1 HRS and beyond. <i>Hepatology</i> , 2006, 43, 385-394.	3.6	126
66	The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis. <i>Hepatology</i> , 2006, 44, 640-649.	3.6	4
67	Model for end-stage liver disease (MELD) exception for ascites. <i>Liver Transplantation</i> , 2006, 12, S88-S90.	1.3	9
68	The management and nursing care of cirrhotic ascites. <i>British Journal of Nursing</i> , 2006, 15, 212-219.	0.3	10
69	Management of patients with advanced liver cirrhosis. <i>Nursing Standard (Royal College of Nursing)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.1	10
70	MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. <i>Gut</i> , 2007, 56, 1283-1290.	6.1	180
72	Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. <i>Journal of Hepatology</i> , 2007, 46, 387-394.	1.8	258
74	Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2007, 133, 825-834.	0.6	494
75	Drug Insight: the role of albumin in the management of chronic liver disease. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2007, 4, 43-51.	1.7	68
76	Evaluation of reagent strips for ascitic fluid leukocyte determination: is it a possible alternative for spontaneous bacterial peritonitis rapid diagnosis?. <i>Brazilian Journal of Infectious Diseases</i> , 2007, 11, 70-74.	0.3	11
77	Pathophysiology of ascites and dilutional hyponatremia: Contemporary use of aquaretic agents. <i>Annals of Hepatology</i> , 2007, 6, 214-221.	0.6	24
78	Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. <i>Hepatology</i> , 2007, 46, 1863-1871.	3.6	126
79	Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. <i>Hepatology</i> , 2007, 47, 160-168.	3.6	41
80	The patient with refractory ascites. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 551-560.	1.0	16

#	ARTICLE	IF	CITATIONS
81	Tc-99m tetrofosmin uptake in a male patient with gynecomastia. <i>Journal of Nuclear Cardiology</i> , 2007, 14, 902-903.	1.4	3
82	Proteomics analysis of serous fluids and effusions: Pleural, pericardial, and peritoneal. <i>Proteomics - Clinical Applications</i> , 2007, 1, 834-844.	0.8	11
83	Hepatic hydrothorax: Pathophysiology diagnosis and management. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1388-1393.	1.4	53
84	Review article: management of ascites and associated complications in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 183-193.	1.9	84
85	An Evidence-Based Manual for Abdominal Paracentesis. <i>Digestive Diseases and Sciences</i> , 2007, 52, 3307-3315.	1.1	59
86	Management of ascites and hepatic hydrothorax. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 55-75.	1.0	36
87	Portale Hypertension. <i>Wiener Klinische Wochenschrift Education</i> , 2008, 3, 107-118.	0.0	0
88	What's new in the treatment of ascites and spontaneous bacterial peritonitis. <i>Current Gastroenterology Reports</i> , 2008, 10, 7-14.	1.1	9
89	Pathogenetic background for treatment of ascites and hepatorenal syndrome. <i>Hepatology International</i> , 2008, 2, 416-428.	1.9	47
90	Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1377-1384.	1.2	67
91	Effects of sivataptan, a selective vasopressin V <sub>2</sub> receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. <i>Hepatology</i> , 2008, 48, 204-213.	3.6	183
92	Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1722-1727.	1.4	36
93	Is there yet any place for reagent strips in diagnosing spontaneous bacterial peritonitis in cirrhotic patients? An accuracy and cost-effectiveness study in Brazil. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1895-1900.	1.4	5
99	Portal Hypertension and Its Complications. <i>Gastroenterology</i> , 2008, 134, 1715-1728.	0.6	303
100	Technical Challenges in TIPS Creation via the Right Subclavian Vein. <i>Journal of Vascular and Interventional Radiology</i> , 2008, 19, 1777-1780.	0.2	0
102	Are ascitic electrolytes usable in cirrhotic patients? Correlation of sodium, potassium, chloride, urea, and creatinine concentrations in ascitic fluid and blood. <i>European Journal of Internal Medicine</i> , 2008, 19, 613-618.	1.0	11
103	Protocolo diagnóstico etiológico de la ascitis. <i>Medicine</i> , 2008, 10, 733-736.	0.0	0
104	Recent role of splenectomy in chronic hepatic disorders. <i>Hepatology Research</i> , 2008, 38, 1159-1171.	1.8	37

#	ARTICLE	IF	CITATIONS
106	Fluid retention in cirrhosis: pathophysiology and management. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 71-85.	0.2	75
107	Emerging drugs for complications of end-stage liver disease. Expert Opinion on Emerging Drugs, 2008, 13, 159-174.	1.0	1
108	The Management of Ascites and Hyponatremia in Cirrhosis. Seminars in Liver Disease, 2008, 28, 043-058.	1.8	79
109	Concave Margin Sign on CT as an Indication of Ascites. Radiology Case Reports, 2008, 3, 199.	0.2	2
110	Spontaneous bacterial peritonitis: How to deal with this life-threatening cirrhosis complication?. Therapeutics and Clinical Risk Management, 2008, Volume 4, 919-925.	0.9	27
111	Ascitic fluid analysis for diagnosis and monitoring of spontaneous bacterial peritonitis. World Journal of Gastroenterology, 2009, 15, 3845.	1.4	31
112	Management of ascites due to gastrointestinal malignancy. Annals of Saudi Medicine, 2009, 29, 369-377.	0.5	83
113	The Association Between the Serum Sodium Level and the Severity of Complications in Liver Cirrhosis. Korean Journal of Internal Medicine, 2009, 24, 106.	0.7	36
114	Routine review of ascites fluid from patients with cirrhosis or hepatocellular carcinoma is a low-yield procedure: An observational study. CytoJournal, 2009, 6, 16.	0.8	15
116	Spot urinary sodium for assessing dietary sodium restriction in cirrhotic ascites. World Journal of Gastroenterology, 2009, 15, 3631.	1.4	30
117	Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost. Liver Transplantation, 2009, 15, 148-162.	1.3	48
118	Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatology International, 2009, 3, 582-586.	1.9	86
119	Ascites and spontaneous bacterial peritonitis: An Asian perspective. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1494-1503.	1.4	29
120	The effect of 1 month of therapy with midodrine, octreotide and albumin in refractory ascites: a pilot study. Liver International, 2009, 29, 169-174.	1.9	40
121	Is albumin infusion necessary after large volume paracentesis? Pro main arguments. Liver International, 2009, 29, 636-638.	1.9	23
123	Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. American Journal of Gastroenterology, 2009, 104, 1802-1829.	0.2	215
124	The Use of E/A Ratio as a Predictor of Outcome in Cirrhotic Patients Treated With Transjugular Intrahepatic Portosystemic Shunt. American Journal of Gastroenterology, 2009, 104, 2458-2466.	0.2	160
125	Ascites: Diagnosis and Management. Medical Clinics of North America, 2009, 93, 801-817.	1.1	87

#	ARTICLE	IF	CITATIONS
126	Ascites: Pathogenesis and therapeutic principles. Scandinavian Journal of Gastroenterology, 2009, 44, 902-911.	0.6	47
127	Renal Failure in Cirrhosis. New England Journal of Medicine, 2009, 361, 1279-1290.	13.9	713
128	Primary biliary cirrhosis presenting with ascites and a hepatic hydrothorax: a case report. Journal of Medical Case Reports, 2009, 3, 7371.	0.4	1
129	Ascites: Aetiology, mortality and the prevalence of spontaneous bacterial peritonitis. Scandinavian Journal of Gastroenterology, 2009, 44, 970-974.	0.6	34
131	Value of the extracellular water ratio for assessment of cirrhotic patients with and without ascites. Hepatology Research, 2009, 39, 1072-1079.	1.8	25
132	Risk Factors and Management of Ascites After Liver Resection to Treat Hepatocellular Carcinoma. Archives of Surgery, 2009, 144, 46.	2.3	169
133	Bacterial Meningitis in Cirrhotic Patients. Journal of Clinical Gastroenterology, 2010, 44, e218-e223.	1.1	8
134	Serum Sodium Predicts Prognosis in Critically Ill Cirrhotic Patients. Journal of Clinical Gastroenterology, 2010, 44, 220-226.	1.1	77
135	Terlipressin for Hepatorenal Syndrome: Novel Strategies and Future Perspectives. Frontiers of Gastrointestinal Research, 2010, , 189-197.	0.1	2
137	Colloid solutions: a clinical update. Journal of Anesthesia, 2010, 24, 913-925.	0.7	46
138	Evaluation of leucocyte esterase reagent strip test for the rapid bedside diagnosis of spontaneous bacterial peritonitis. Indian Journal of Gastroenterology, 2010, 29, 74-77.	0.7	10
139	Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology, 2010, 52, 1017-1022.	3.6	452
140	Beta-blockers in cirrhosis: Friend and foe?. Hepatology, 2010, 52, 811-813.	3.6	43
141	Comparison study of Doppler ultrasound surveillance of expanded polytetrafluoroethylene-covered stent versus bare stent in transjugular intrahepatic portosystemic shunt. Journal of Clinical Ultrasound, 2010, 38, 353-360.	0.4	28
142	Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V <sub>2</sub> receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double-blind, placebo-controlled study. Alimentary Pharmacology and Therapeutics, 2010, 31, 834-845.	1.9	39
143	Impact of preoperative serum sodium concentration in living donor liver transplantation. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 978-984.	1.4	16
144	Vaptans for Ascites – Chances and Risks. Frontiers of Gastrointestinal Research, 2010, , 91-101.	0.1	0
145	Current Treatment Strategies: Diuretics. Frontiers of Gastrointestinal Research, 2010, , 11-22.	0.1	0



#	ARTICLE	IF	CITATIONS
147	Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. <i>Gut</i> , 2010, 59, 381-386.	6.1	83
148	Amiloride reduces portal hypertension in rat liver cirrhosis. <i>Gut</i> , 2010, 59, 827-836.	6.1	21
149	Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. <i>Gut</i> , 2010, 59, 1561-1569.	6.1	226
151	Optimum use of diuretics in managing ascites in patients with cirrhosis. <i>Gut</i> , 2010, 59, 10-11.	6.1	18
152	Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome. <i>Kidney International</i> , 2010, 77, 669-680.	2.6	32
153	Predictors of large volume paracentesis induced circulatory dysfunction in patients with massive hepatic ascites. <i>Journal of Cardiovascular Disease Research (discontinued)</i> , 2010, 1, 136-144.	0.1	29
154	Factors That Predict Outcome of Abdominal Operations in Patients With Advanced Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 451-457.	2.4	120
155	Incidence and Prognosis of Different Types of Functional Renal Failure in Cirrhotic Patients With Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 616-622.	2.4	82
157	Hepatorenal Syndrome: A Comprehensive Overview for the Critical Care Nurse. <i>Critical Care Nursing Clinics of North America</i> , 2010, 22, 351-368.	0.4	1
158	Therapierefraktärer Aszites. <i>DoctorConsult - the Journal Wissen Für Klinik Und Praxis</i> , 2010, 1, e195-e197.	0.0	0
159	Long-term effect of liver transplantation on cirrhotic autonomic cardiac dysfunction. <i>Digestive and Liver Disease</i> , 2010, 42, 131-136.	0.4	15
160	Effects of a selective vasopressin V2 receptor antagonist, sivataptan, on ascites recurrence after paracentesis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2010, 53, 283-290.	1.8	78
161	May vaptans contribute to the treatment of refractory ascites?. <i>Journal of Hepatology</i> , 2010, 53, 225-227.	1.8	0
162	EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. <i>Journal of Hepatology</i> , 2010, 53, 397-417.	1.8	1,490
164	Chronic Kidney Disease—Epidemiology Formula and Model for End-Stage Liver Disease Score in the Assessment of Renal Function in Candidates for Liver Transplantation. <i>Transplantation Proceedings</i> , 2010, 42, 1229-1232.	0.3	7
165	Effects of terlipressin on water excretion after oral water load test in nonazotemic cirrhotic patients with ascites without hyponatremia. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 1509-1515.	0.6	10
166	Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. <i>Gut</i> , 2010, 59, 98-104.	6.1	122
167	Use of Diuretics in Heart Failure and Cirrhosis. <i>Seminars in Nephrology</i> , 2011, 31, 503-512.	0.6	26

#	ARTICLE	IF	CITATIONS
168	Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation?. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 931-935.	2.4	3
169	Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis. <i>Gastroenterology</i> , 2011, 140, 488-496.e4.	0.6	311
170	Therapie des zirrhatischen Aszites. <i>DoctorConsult - the Journal Wissen Fur Klinik Und Praxis</i> , 2011, 2, 69-73.	0.0	0
171	Therapie des zirrhatischen Aszites. <i>DoctorConsult - the Journal Wissen Fur Klinik Und Praxis</i> , 2011, 2, e192-e196.	0.0	0
172	Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: Standard vs half albumin doses. A prospective, randomized, unblinded pilot study. <i>Digestive and Liver Disease</i> , 2011, 43, 881-6.	0.4	54
173	Hepatorenal syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1405-1417.	0.9	20
174	Homozygous carrier of the <i>NOD2</i> 1007fs frameshift mutation presenting with refractory community-acquired spontaneous bacterial peritonitis and developing fatal pulmonary mucormycosis: A case report. <i>Hepatology Research</i> , 2011, 41, 1009-1014.	1.8	2
175	Management of hepatorenal syndrome in patients with cirrhosis. <i>Nature Reviews Nephrology</i> , 2011, 7, 517-526.	4.1	58
176	Management of patients with cirrhosis awaiting liver transplantation. <i>Gut</i> , 2011, 60, 412-421.	6.1	64
177	The Amount of Alcohol Consumption Negatively Impacts Short-Term Mortality in Mexican Patients With Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2011, 106, 1472-1480.	0.2	33
178	Intravenous High-Dose Furosemide and Hypertonic Saline Solutions for Refractory Heart Failure and Ascites. <i>Seminars in Nephrology</i> , 2011, 31, 513-522.	0.6	24
179	The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: A multicentric study. <i>European Journal of Internal Medicine</i> , 2011, 22, 587-590.	1.0	30
180	Serum bilirubin and platelet count: A simple predictive model for survival in patients with refractory ascites treated by TIPS. <i>Journal of Hepatology</i> , 2011, 54, 901-907.	1.8	94
181	Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: A cross-over study. <i>Journal of Hepatology</i> , 2011, 55, 794-799.	1.8	177
182	Medical management of ascites. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1269-1283.	0.9	9
183	Preoperative Natriuretic Peptide-B Values and Ascites in Male Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2011, 43, 705-707.	0.3	4
184	Current indications for the use of albumin in the treatment of cirrhosis. <i>Annals of Hepatology</i> , 2011, 10, S15-S20.	0.6	24
186	Diagnosis and therapy of ascites in liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2011, 17, 1237.	1.4	80

#	ARTICLE	IF	CITATIONS
187	Management of end-stage liver disease in HIV/hepatitis C virus co-infection. Current Opinion in HIV and AIDS, 2011, 6, 527-533.	1.5	12
189	Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. Journal of Gastroenterology, 2011, 46, 78-85.	2.3	139
190	Management of Refractory Ascites and Hepatorenal Syndrome. Current Gastroenterology Reports, 2011, 13, 17-25.	1.1	7
191	How much is too much?. Liver Transplantation, 2011, 17, 102-103.	1.3	0
192	Splenic artery embolization for the treatment of refractory ascites after liver transplantation. Liver Transplantation, 2011, 17, 668-673.	1.3	39
193	Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score-based liver allocation system. Liver Transplantation, 2011, 17, 1137-1151.	1.3	68
194	Autopsy findings of a patient with rapidly progressive massive ascites caused by alcoholic cirrhosis. Legal Medicine, 2011, 13, 148-150.	0.6	2
195	Critical Flicker Frequency as a Marker of Hepatic Encephalopathy in Patients before and after Transjugular Intrahepatic Portosystemic Shunt. Digestion, 2011, 83, 24-31.	1.2	11
196	Management of Renal Failure and Ascites in Patients with Cirrhosis. International Journal of Hepatology, 2011, 2011, 1-7.	0.4	6
197	Clinical Spectrum of Renal Disorders in Patients with Cirrhosis of Liver. Renal Failure, 2011, 33, 40-46.	0.8	29
198	Diagnosis and management of chronic liver disease in older people. Reviews in Clinical Gerontology, 2011, 21, 1-15.	0.5	10
199	Ascites in Adult Patients With Cyanotic Congenital Heart Disease. World Journal for Pediatric & Congenital Heart Surgery, 2011, 2, 97-103.	0.3	2
200	Ascites and spontaneous bacterial peritonitis. , 2012, , 159-172.		0
201	<i>Listeria monocytogenes</i> peritonitis: presentation, clinical features, treatment, and outcome. Scandinavian Journal of Gastroenterology, 2012, 47, 1129-1140.	0.6	21
202	In-111 transferrin scintigraphy in cirrhosis with hypoalbuminemia: Evidence for protein-losing enteropathy in a small group of selected cases. Scandinavian Journal of Gastroenterology, 2012, 47, 1247-1252.	0.6	11
203	Management of Refractory Ascites. American Journal of Therapeutics, 2012, 19, 121-132.	0.5	31
204	Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut, 2012, 61, 108-116.	6.1	121
205	Terlipressin Resolves Ascites of Cirrhotic Rats through Downregulation of Aquaporin 2. Journal of International Medical Research, 2012, 40, 1735-1744.	0.4	6

#	ARTICLE	IF	CITATIONS
206	Fluid, Electrolyte, and Acid-Base Disturbances in Liver Disease. , 2012, , 456-499.		2
207	The Pharmacokinetics and Pharmacodynamics of Tolvaptan in Patients with Liver Cirrhosis with Insufficient Response to Conventional Diuretics: a Multicentre, Double-blind, Parallel-group, Phase III Study. <i>Journal of International Medical Research</i> , 2012, 40, 2381-2393.	0.4	32
208	Thyroid and Hepatic Haemodynamic Alterations among Egyptian Children with Liver Cirrhosis. <i>ISRN Gastroenterology</i> , 2012, 2012, 1-7.	1.5	13
209	Improving Survival in Decompensated Cirrhosis. <i>International Journal of Hepatology</i> , 2012, 2012, 1-14.	0.4	26
210	Clinical Manifestations of Portal Hypertension. <i>International Journal of Hepatology</i> , 2012, 2012, 1-10.	0.4	79
212	Ascitis y sãAndrome hepatorrenal. <i>Medicine</i> , 2012, 11, 644-651.	0.0	0
213	Prognostic criteria for postoperative mortality in 170 patients undergoing major right hepatectomy. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2012, 11, 507-512.	0.6	15
214	Predictors of Posthepatectomy Ascites with or without Previous Portal Vein Embolization. <i>Digestive Surgery</i> , 2012, 29, 468-474.	0.6	10
215	Analytical evaluation of Sysmex UF-1000i for flow cytometric analysis of peritoneal fluid. <i>Clinical Biochemistry</i> , 2012, 45, 1263-1265.	0.8	25
216	Intra- and Interoperator Reproducibility of Acoustic Radiation Force Impulse (ARFI) Elastographyâ€Preliminary Results. <i>Ultrasound in Medicine and Biology</i> , 2012, 38, 1103-1108.	0.7	90
217	Acute Kidney Injury Is an Early Predictor of Mortality for Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 65-71.e3.	2.4	155
218	The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1169-1175.	2.4	28
220	Midodrine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study. <i>Journal of Hepatology</i> , 2012, 56, 348-354.	1.8	85
221	Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites. <i>Journal of Hepatology</i> , 2012, 57, 274-280.	1.8	67
222	Quantitative modeling of the physiology of ascites in portal hypertension. <i>BMC Gastroenterology</i> , 2012, 12, 26.	0.8	10
224	Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure. <i>Gastroenterology</i> , 2012, 142, 782-789.e3.	0.6	355
225	Cirrhotic and malignant ascites: Differential CT diagnosis. <i>Diagnostic and Interventional Imaging</i> , 2012, 93, 365-370.	1.8	20
226	Revision and update on clinical practice guideline for liver cirrhosis. <i>The Korean Journal of Hepatology</i> , 2012, 18, 1.	1.5	120

#	ARTICLE	IF	CITATIONS
227	Transjugular Intrahepatic Portosystemic Shunt for Portal Cavernoma with Symptomatic Portal Hypertension in Non-cirrhotic Patients. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1072-1082.	1.1	159
228	Management of ascites in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 11-20.	1.4	68
229	Transjugular intrahepatic portosystemic shunt for hepatitis C virus-related portal hypertension after liver transplantation. <i>Clinical Transplantation</i> , 2012, 26, 699-705.	0.8	8
230	Adverse Outcomes in Patients with Postoperative Ascites after Liver Resection for Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2012, 36, 392-400.	0.8	44
231	Multivariate comparison of B-ultrasound guided and laparoscopic continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy for malignant ascites. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 2735-2743.	1.3	22
232	Effects of transjugular intrahepatic portosystemic shunt on changes in the small bowel mucosa of cirrhotic patients with portal hypertension. <i>Journal of Gastroenterology</i> , 2013, 48, 633-639.	2.3	14
233	Prevalence of and clinicopathologic findings associated with ascites in dogs in Enugu State, Nigeria. <i>Comparative Clinical Pathology</i> , 2013, 22, 185-193.	0.3	7
234	Safety and efficacy of radiological percutaneous jejunostomy for decompression of malignant small bowel obstruction. <i>European Radiology</i> , 2013, 23, 2747-2753.	2.3	14
235	Portale Hypertension. <i>Wiener Klinische Wochenschrift Education</i> , 2013, 8, 1-13.	0.0	0
236	Ascites as the Initial Presentation of Gastrointestinal Carcinoma. <i>Journal of Emergency Medicine</i> , 2013, 44, e195-e198.	0.3	3
237	Evidence-Based Review of the Management of Hepatic Hydrothorax. <i>Respiration</i> , 2013, 86, 155-173.	1.2	65
238	Evaluation of white blood cell count in peritoneal fluid with five different hemocytometers. <i>Clinical Biochemistry</i> , 2013, 46, 173-176.	0.8	18
239	Association Between Ratio of Sodium to Potassium in Random Urine Samples and Renal Dysfunction and Mortality in Patients With Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 862-867.	2.4	11
240	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1426-1437.e9.	0.6	2,211
241	Assessment of neutrophil gelatinase-associated lipocalin and lactate dehydrogenase in peritoneal fluids for the screening of bacterial peritonitis. <i>Clinica Chimica Acta</i> , 2013, 418, 59-62.	0.5	17
242	Hemorrhagic ascites. Clinical presentation and outcomes in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 1113-1118.	1.8	29
243	Mortality after urinary tract infections in patients with advanced cirrhosis – Relevance of acute kidney injury and comorbidities. <i>Liver International</i> , 2013, 33, 220-230.	1.9	19
244	Management of ascites in patients with liver cirrhosis: Recent evidence and controversies. <i>Journal of the Chinese Medical Association</i> , 2013, 76, 123-130.	0.6	26

#	ARTICLE	IF	CITATIONS
245	Midodrine and Clonidine in Patients With Cirrhosis and Refractory or Recurrent Ascites: A Randomized Pilot Study. <i>American Journal of Gastroenterology</i> , 2013, 108, 560-567.	0.2	44
246	Peritoneal Fluid Accumulation in Healthy Men and Postmenopausal Women: Evaluation on Pelvic MRI. <i>American Journal of Roentgenology</i> , 2013, 200, 1181-1185.	1.0	9
247	Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 200-219.	1.0	43
248	Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2013, 3, e003370.	0.8	6
249	Increased nitric oxide production in lymphatic endothelial cells causes impairment of lymphatic drainage in cirrhotic rats. <i>Gut</i> , 2013, 62, 138-145.	6.1	47
250	Clinical Characteristics of Patients with Hepatocellular Carcinoma in a Middle Eastern Population. <i>Hepatitis Monthly</i> , 2013, 13, e7612.	0.1	21
251	Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. <i>Journal of International Medical Research</i> , 2013, 41, 835-847.	0.4	48
252	Evaluation of the Fully Automated Hematological Analyzer Sysmex XE-5000 for Flow Cytometric Analysis of Peritoneal Fluid. <i>Journal of the Association for Laboratory Automation</i> , 2013, 18, 240-244.	2.8	11
253	Tolvaptan, an orally active non-peptide arginine vasopressin $V_2$ receptor antagonist, reduces ascites in rats with chronic liver injury. <i>Hepatology Research</i> , 2013, 43, 1224-1230.	1.8	5
254	The liver to abdominal area ratio (LAAR): a novel imaging score for prognostication in cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1385-1394.	1.9	6
255	Current management of uncomplicated ascites. <i>Clinical Liver Disease</i> , 2013, 2, 125-127.	1.0	0
256	Acute-on-chronic liver failure: Is the definition ready for prime time?. <i>Clinical Liver Disease</i> , 2013, 2, 113-115.	1.0	3
257	Predicting the development of acute kidney injury in liver cirrhosis – an analysis of glomerular filtration rate, proteinuria and kidney injury biomarkers. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 989-997.	1.9	34
258	Recognition, treatment and management of hepatorenal syndrome. <i>Gastrointestinal Nursing</i> , 2013, 11, 42-48.	0.0	2
259	Predictors of Refractory Ascites Development in Patients with Hepatitis B Virus-Related Cirrhosis Hospitalized to Control Ascitic Decompensation. <i>Yonsei Medical Journal</i> , 2013, 54, 145.	0.9	4
260	Child-Na Score: A Predictive Model for Survival in Cirrhotic Patients with Symptomatic Portal Hypertension Treated with TIPS. <i>PLoS ONE</i> , 2013, 8, e79637.	1.1	10
261	Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites. <i>Journal of Clinical and Translational Hepatology</i> , 2014, 2, 58-64.	0.7	46
262	Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs. <i>Current Vascular Pharmacology</i> , 2014, 12, 125-135.	0.8	24

#	ARTICLE	IF	CITATIONS
263	Decompensated cirrhosis-related admissions in a large urban hospital in Uganda: prevalence, clinical and laboratory features and implications for planning patient management. <i>African Health Sciences</i> , 2014, 13, 927.	0.3	10
264	Refractory Ascites in Cirrhosis: Prevalence and Predictive Factors. <i>Journal of Liver</i> , 2014, 03, .	0.3	0
265	Outcomes of Transjugular Intrahepatic Portosystemic Shunts for Ascites. <i>Seminars in Interventional Radiology</i> , 2014, 31, 248-251.	0.3	3
266	Correlation between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with hepatic edema in short-term diuretic therapy. <i>Hepatology Research</i> , 2014, 44, 735-739.	1.8	17
267	Open-label randomized controlled trial to compare diuretic therapy with recombinant human serum albumin and diuretic therapy for therapeutic treatment of ascites in patients with advanced liver cirrhosis: An exploratory trial. <i>Hepatology Research</i> , 2014, 44, 502-514.	1.8	6
268	Predictive factors for improvement of ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites. <i>Hepatology Research</i> , 2014, 44, 871-877.	1.8	16
269	Monitoring and Care. , 2014, , 478-493.		0
270	Outpatient Interventions for Hepatology Patients With Fluid Retention. <i>Gastroenterology Nursing</i> , 2014, 37, 236-244.	0.2	5
271	Hepatic Hydrothorax. <i>American Journal of Therapeutics</i> , 2014, 21, 43-51.	0.5	14
272	Organ dysfunctions in patients with alcoholic cirrhosis. <i>Hepatology International</i> , 2014, 8, 464-466.	1.9	1
273	Hemorrhagic Complications of Paracentesis: A Systematic Review of the Literature. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-6.	0.7	45
274	Ascites and spontaneous bacterial peritonitis: Recommendations from two United States centers. <i>Saudi Journal of Gastroenterology</i> , 2014, 20, 279.	0.5	17
275	Refractory Ascites: How to Establish the Diagnosis and What Can Be Done?. <i>Current Hepatitis Reports</i> , 2014, 13, 50-59.	0.3	0
276	Effects of paracentesis on hemodynamic parameters and respiratory function in critically ill patients. <i>BMC Gastroenterology</i> , 2014, 14, 18.	0.8	12
277	Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis. <i>Hepatology Research</i> , 2014, 44, 621-630.	1.8	36
278	Application of an isocratic methanol-based HPLC method for the determination of iohexol concentrations and glomerular filtration rate in patients with cirrhosis. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 80-88.	0.8	8
279	Prognostic factors in patients with refractory ascites treated by transjugular intrahepatic porto-systemic shunt: From the liver to the kidney. <i>Digestive and Liver Disease</i> , 2014, 46, 1001-1007.	0.4	10
280	Paracentesis-induced inflammation: a new syndrome?. <i>Liver International</i> , 2014, 34, 974-975.	1.9	0

#	ARTICLE	IF	CITATIONS
281	The utility of scoring systems in critically ill cirrhotic patients admitted to a general intensive care unit. <i>Journal of Critical Care</i> , 2014, 29, 1131.e1-1131.e6.	1.0	17
282	Stage of cirrhosis predicts the risk of liver-related death in patients with low model for End-Stage liver disease scores and cirrhosis awaiting liver transplantation. <i>Liver Transplantation</i> , 2014, 20, 1193-1201.	1.3	41
283	Intensive Care Unit Management of Patients with Liver Failure. <i>Clinics in Liver Disease</i> , 2014, 18, 957-978.	1.0	22
284	Use of a transjugular intrahepatic portosystemic shunt combined with autologous bone marrow cell infusion in patients with decompensated liver cirrhosis: an exploratory study. <i>Cytotherapy</i> , 2014, 16, 1575-1583.	0.3	2
285	A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2014, 146, 1231-1239.e6.	0.6	353
286	Non-hepatic gastrointestinal surgery in patients with cirrhosis. <i>Journal of Visceral Surgery</i> , 2014, 151, 203-211.	0.4	25
288	Risk factors for early rebleeding and mortality in acute variceal hemorrhage. <i>World Journal of Gastroenterology</i> , 2014, 20, 17941-17948.	1.4	21
289	Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: The Critical Flicker Frequency is more accurate than psychometric tests. <i>Hepatology</i> , 2014, 59, 622-629.	3.6	62
290	Hepatic Hydrothorax. <i>Medicine (United States)</i> , 2014, 93, 135-142.	0.4	111
291	Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. <i>Liver Transplantation</i> , 2015, 21, 1347-1354.	1.3	48
292	The safety and efficacy of prednisolone in preventing reaccumulation of ascites among endomyocardial fibrosis patients in Uganda: a randomized clinical trial. <i>BMC Research Notes</i> , 2015, 8, 783.	0.6	3
293	Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 126-136.	1.9	42
294	In-hospital mortality risk factors in patients with ascites due to cirrhosis. <i>Revista Da Associação Médica Brasileira</i> , 2015, 61, 35-39.	0.3	8
295	Causes, management and complications of ascites: a review. <i>International Current Pharmaceutical Journal</i> , 2015, 4, 370-377.	0.2	4
296	EVALUATION OF LEUKOCYTE ESTERASE REAGENT STRIPS TEST IN THE DIAGNOSIS OF SPONTANEOUS BACTERIAL PERITONITIS IN CHILDREN WITH CIRRHOSIS. <i>Arquivos De Gastroenterologia</i> , 2015, 52, 195-199.	0.3	4
297	Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management. <i>World Journal of Gastroenterology</i> , 2015, 21, 12125.	1.4	51
298	Expanding consensus in portal hypertension. <i>Journal of Hepatology</i> , 2015, 63, 743-752.	1.8	2,604
299	Diagnosing bacterial peritonitis made easy by use of leukocyte esterase dipsticks. <i>International Journal of Critical Illness and Injury Science</i> , 2015, 5, 32.	0.2	6



#	ARTICLE	IF	CITATIONS
300	Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension. <i>Medicine (United States)</i> , 2015, 94, e1056.	0.4	16
301	Automated low flow pump system for the treatment of refractory ascites: a single-center experience. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 979-983.	0.8	28
302	Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance. <i>Biomedical Reports</i> , 2015, 3, 884-886.	0.9	9
303	Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation. <i>Journal of Hepatology</i> , 2015, 63, 50-59.	1.8	76
305	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. <i>Liver International</i> , 2015, 35, 2121-2128.	1.9	72
306	Treatment and management of ascites and hepatorenal syndrome: an update. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 83-100.	1.4	29
307	Interactions between virus-related factors and post-transplant ascites in patients with hepatitis C and no cirrhosis: role of cryoglobulinemia. <i>Transplant International</i> , 2015, 28, 162-169.	0.8	4
308	Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan. <i>Journal of Gastroenterology</i> , 2015, 50, 1047-1053.	2.3	30
309	Ventral Segmentâ€Preserving Right Hepatectomy in Patients with Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2015, 39, 1034-1043.	0.8	2
310	Contemporary Perspectives on the Pathophysiology and Management of Hepatic Hydrothorax. <i>Current Hepatology Reports</i> , 2015, 14, 212-218.	0.4	1
311	Adrenal function and microbial DNA in noninfected cirrhotic patients with ascites: Relationship and effect on survival. <i>Digestive and Liver Disease</i> , 2015, 47, 702-708.	0.4	7
312	Complications of cirrhosis. A 50 years flashback. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 763-780.	0.6	19
313	Ascites and Refractory Ascites. , 2015, , 121-129.		0
314	Management of cirrhotic ascites. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 124-137.	1.1	55
315	Traditional Iranian medicine: The use of the Canon of medicine by Avicenna to treat ascites. <i>European Journal of Integrative Medicine</i> , 2015, 7, 674-678.	0.8	2
316	Two Unusual but Treatable Causes of Refractory Ascites After Liver Transplantation. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 1663-1669.	0.9	1
317	<sc>CLIF</sc>â€<sc>SOFA</sc> scoring system accurately predicts shortâ€term mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis. <i>Liver International</i> , 2015, 35, 46-57.	1.9	55
318	Managing complications in cirrhotic patients. <i>United European Gastroenterology Journal</i> , 2015, 3, 80-94.	1.6	9

#	ARTICLE	IF	CITATIONS
319	Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 129-137.	0.6	34
320	Acute-on-Chronic Liver Failure: A New Clinical Entity. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 836-841.	2.4	49
321	Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study. <i>Liver International</i> , 2015, 35, 1508-1515.	1.9	63
322	Renal Insufficiency in the Patient with Chronic Liver Disease. <i>Clinics in Liver Disease</i> , 2015, 19, 45-56.	1.0	14
323	Serum Leptin Is a Biomarker of Malnutrition in Decompensated Cirrhosis. <i>PLoS ONE</i> , 2016, 11, e0159142.	1.1	23
324	Epidemiology, Risk Factors, and In-Hospital Mortality of Venous Thromboembolism in Liver Cirrhosis: A Single-Center Retrospective Observational Study. <i>Medical Science Monitor</i> , 2016, 22, 969-976.	0.5	14
325	The role of ascitic fluid viscosity in differentiating the nature of ascites and in the prediction of renal impairment and duration of ICU stay. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1021-1027.	0.8	2
326	Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection. <i>Liver International</i> , 2016, 36, 1628-1638.	1.9	19
327	Manejo de la ascitis refractaria. <i>Medicine</i> , 2016, 12, 707-710.	0.0	0
328	Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis. <i>Internal Medicine</i> , 2016, 55, 2911-2916.	0.3	21
329	Large-volume paracentesis with indwelling peritoneal catheter and albumin infusion: a community hospital study. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2016, 6, 32421.	0.4	10
330	Splenic Artery Syndrome as a Possible Cause of Late Onset Refractory Ascites After Liver Transplantation: Management With Proximal Splenic Artery Embolization. <i>Transplantation Proceedings</i> , 2016, 48, 377-379.	0.3	7
331	Non-HFE iron overload as a surrogate marker of disease severity in patients of liver cirrhosis. <i>Indian Journal of Gastroenterology</i> , 2016, 35, 33-39.	0.7	3
332	The Impact of Tunneled Catheters for Ascites and Peritoneal Carcinomatosis on Patient Rehospitalizations. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 711-716.	0.9	14
333	Behavior and clinical impact of ascites after living donor liver transplantation: risk factors associated with massive ascites. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2016, 23, 688-696.	1.4	15
334	Usefulness of ascitic fluid lactoferrin levels in patients with liver cirrhosis. <i>BMC Gastroenterology</i> , 2016, 16, 132.	0.8	12
335	Prevalence, Risk Factors and In-hospital Outcomes of QTc Interval Prolongation in Liver Cirrhosis. <i>American Journal of the Medical Sciences</i> , 2016, 352, 285-295.	0.4	22
337	Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1455-1461.	0.8	21

#	ARTICLE	IF	CITATIONS
338	Clinical characteristics and outcome of cirrhotic patients with high protein concentrations in ascites. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1268-1274.	0.8	3
339	Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers. <i>Liver International</i> , 2016, 36, 1304-1312.	1.9	67
340	Wall suction-assisted image-guided therapeutic paracentesis: a safe and less expensive alternative to evacuated bottles. <i>Abdominal Radiology</i> , 2016, 41, 1333-1337.	1.0	4
341	Ascites in Children. <i>Indian Journal of Pediatrics</i> , 2016, 83, 1334-1340.	0.3	13
342	The Circulatory System in Liver Disease. <i>Critical Care Clinics</i> , 2016, 32, 331-342.	1.0	18
343	Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. <i>Human Reproduction</i> , 2016, 31, 1997-2004.	0.4	118
344	Sodium restriction in patients with cirrhotic ascites: a protocol for a systematic review. <i>Systematic Reviews</i> , 2016, 5, 78.	2.5	3
345	Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis: outcomes and predictors in a prospective cohort study. <i>Liver International</i> , 2016, 36, 667-676.	1.9	51
346	Cirrhosis-related musculoskeletal disease: radiological review. <i>British Journal of Radiology</i> , 2016, 89, 20150450.	1.0	12
347	AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, 4-15.	0.4	24
348	Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. <i>Hepatology International</i> , 2016, 10, 377-385.	1.9	45
349	The Beneficial Effect of Beta-Blockers in Patients With Cirrhosis, Portal Hypertension and Ascites. <i>American Journal of the Medical Sciences</i> , 2016, 351, 169-176.	0.4	20
350	Nonselective Î²-Blockers and Survival in Patients With Cirrhosis and Ascites: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1096-1104.e9.	2.4	66
351	Transjugular Intrahepatic Porto-Systemic Shunt in Patients with Liver Cirrhosis and Model for End-Stage Liver Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 534-542.	1.1	15
352	Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis. <i>Journal of Gastroenterology</i> , 2017, 52, 229-236.	2.3	18
353	Outcomes of surgical shunts and transjugular intrahepatic portosystemic stent shunts for complicated portal hypertension. <i>British Journal of Surgery</i> , 2017, 104, 443-451.	0.1	15
354	Pro-Brain Natriuretic Peptide and Troponin T-Hypersensitivity Levels Correlate With the Severity of Liver Dysfunction in Liver Cirrhosis. <i>American Journal of the Medical Sciences</i> , 2017, 354, 131-139.	0.4	10
355	Diagnosing Sarcopenia in Male Patients With Cirrhosis by Dual-Energy X-Ray Absorptiometry Estimates of Appendicular Skeletal Muscle Mass. <i>Journal of Parenteral and Enteral Nutrition</i> , 2018, 42, 24-36.	1.3	40

#	ARTICLE	IF	CITATIONS
356	Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1372-1382.	0.9	22
357	Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention. <i>Digestive Diseases</i> , 2017, 35, 402-410.	0.8	23
358	Characterization of Cerebral Edema in Acute-on-Chronic Liver Failure. <i>Journal of Clinical and Experimental Hepatology</i> , 2017, 7, 190-197.	0.4	17
359	Risk Factors for Postoperative Ascites in Patients Undergoing Liver Resection for Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2017, 41, 2095-2100.	0.8	13
360	A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1413-1426.	1.9	61
361	Toll-like receptor-2 Arg753Gln and Arg677Trp polymorphisms and susceptibility to pulmonary and peritoneal tuberculosis. <i>Apmis</i> , 2017, 125, 558-564.	0.9	16
362	Neutrophil-to-lymphocyte ratio correlates with proinflammatory neutrophils and predicts death in low model for end-stage liver disease patients with cirrhosis. <i>Liver Transplantation</i> , 2017, 23, 155-165.	1.3	74
363	Spironolactone. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 288-292.	0.6	30
364	Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth-III). <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 135-158.	1.0	111
366	Background and design of the symptom burden in end-stage liver disease patient-caregiver dyad study. <i>Research in Nursing and Health</i> , 2017, 40, 398-413.	0.8	16
367	Diuretic Resistance. <i>American Journal of Kidney Diseases</i> , 2017, 69, 136-142.	2.1	87
368	Urine albumin-to-creatinine ratio is associated with the severity of liver disease, renal function and survival in patients with decompensated cirrhosis. <i>Hepatology International</i> , 2017, 11, 306-314.	1.9	9
369	Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study. <i>Liver International</i> , 2017, 37, 406-414.	1.9	16
370	Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis. <i>Liver International</i> , 2017, 37, 224-231.	1.9	47
371	Quantification of ascites based on abdomino-pelvic computed tomography scans for predicting the in-hospital mortality of liver cirrhosis. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 5733-5742.	0.8	7
372	Treatment of refractory ascites -A comparison of CART, TIPS and Denver shunt-. <i>Acta Hepatologica Japonica</i> , 2017, 58, 91-96.	0.0	0
373	Aspiration in injections: should we continue or abandon the practice?. <i>F1000Research</i> , 2014, 3, 157.	0.8	9
374	Trace Elements in Children with Chronic Liver Disease. <i>Journal of Clinical Gastroenterology and Hepatology</i> , 2017, 01, .	0.2	0

#	ARTICLE	IF	CITATIONS
375	Ascites: Treatment, Complications, and Prognosis. , 2017, , .		1
376	Ascites: Causes, Diagnosis, and Treatment. , 0, , .		3
377	CLIF-C ACLF score is a better mortality predictor than MELD, MELD-Na and CTP in patients with Acute on Chronic Liver Failure admitted to the ward. Revista Espanola De Enfermedades Digestivas, 2017, 109, 399-405.	0.1	36
378	Acute-on-chronic liver failure: recent update. Journal of Biomedical Research, 2017, 31, 283.	0.7	20
379	Validation trial for efficacy of ultrasonographic measurement method to predict ascitic volume using virtual ultrasonography. Journal of Medical Ultrasonics (2001), 2018, 45, 555-564.	0.6	1
380	To salt or not to salt?â€”That is the question in cirrhosis. Liver International, 2018, 38, 1148-1159.	1.9	27
381	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology, 2018, 69, 406-460.	1.8	1,762
382	Value of <sup>18</sup> F-FDG PET/CT Combined With Tumor Markers in the Evaluation of Ascites. American Journal of Roentgenology, 2018, 210, 1155-1163.	1.0	5
383	Abdominal paracentesis: use of a standardised procedure checklist and equipment kit improves procedural quality and reduces complications. Internal Medicine Journal, 2018, 48, 572-579.	0.5	9
384	Utilizing Abdominal Sonography in the Diagnosis of Ascites Caused by Heart Failure: A Patient With Cirrhosis. Journal of Diagnostic Medical Sonography, 2018, 34, 50-52.	0.1	2
385	Point-of-Care Ultrasound in the Intensive Care Unit. Clinics in Chest Medicine, 2018, 39, 79-97.	0.8	35
386	Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. Journal of Hepatology, 2018, 68, 949-958.	1.8	108
387	Does Intermittent Pringle Maneuver Increase Postoperative Complications After Hepatectomy for Hepatocellular Carcinoma? A Randomized Controlled Trial. World Journal of Surgery, 2018, 42, 3302-3311.	0.8	24
388	Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2018, 16, 1153-1162.e7.	2.4	90
389	Cell death markers in patients with cirrhosis and acute decompensation. Hepatology, 2018, 67, 989-1002.	3.6	76
390	The qualitative and quantitative image analysis of MR imaging in patients with acute-on-chronic liver failure. Clinical Imaging, 2018, 47, 18-24.	0.8	1
391	Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut, 2018, 67, 2181-2191.	6.1	255
392	Functional polymorphisms of innate immunity receptors are not risk factors for the nonâ€“SBP type bacterial infections in cirrhosis. Liver International, 2018, 38, 1242-1252.	1.9	9

#	ARTICLE	IF	CITATIONS
393	Ischemic stroke in liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 233-240.	0.8	22
394	A simplified prognostic model to predict mortality in patients with acute variceal bleeding. <i>Digestive and Liver Disease</i> , 2018, 50, 247-253.	0.4	17
395	Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1256-1263.	1.4	20
396	Current management of refractory ascites in patients with cirrhosis. <i>Journal of International Medical Research</i> , 2018, 46, 1138-1145.	0.4	18
397	Efficacy and safety of ultrasound guided percutaneous glue embolization in iatrogenic haemorrhagic complications of paracentesis and thoracocentesis in cirrhotic patients. <i>British Journal of Radiology</i> , 2018, 91, 20170259.	1.0	8
398	KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 230-277.	4.5	49
399	A Dynamic Model for Predicting Outcome in Patients with HBV Related Acute-On-Chronic Liver Failure. <i>Annals of Hepatology</i> , 2018, 17, 392-402.	0.6	6
400	Paracentesis: datos sobre la correcta utilizaci3n. <i>Revista Universitas Medica</i> , 2018, 59, .	0.0	0
401	Treatment for ascites in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2018, , .	1.5	1
402	Abdominal Paracentesis: Safety and Efficacy Comparing Medicine Resident Bedside Paracentesis vs. Paracentesis Performed by Interventional Radiology. <i>Journal of Clinical Gastroenterology and Hepatology</i> , 2018, 02, .	0.2	2
403	Vitamin D deficiency is associated with hepatic decompensation and inflammation in patients with liver cirrhosis: A prospective cohort study. <i>PLoS ONE</i> , 2018, 13, e0207162.	1.1	37
404	Ascites and Hyponatremia. , 2018, , 220-232.e4.		1
405	Development and external validation of a prognostic nomogram for acute decompensation of chronic hepatitis B cirrhosis. <i>BMC Gastroenterology</i> , 2018, 18, 179.	0.8	12
406	Transjunosotomy Stent Placement in Patients With Malignant Small-Bowel Obstructions. <i>American Journal of Roentgenology</i> , 2018, 211, 1148-1154.	1.0	4
408	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	6.3	345
409	Automated analysis for differentiating leukocytes in body fluids using the software "œbiological liquid application" on <sc>ADVIA</sc>2120/2120i hematology analyzer. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22578.	0.9	6
410	Transjugular Intrahepatic Portosystemic Shunt Placement for Refractory Ascites: Review and Update of the Literature. <i>Seminars in Interventional Radiology</i> , 2018, 35, 165-168.	0.3	8
411	Palliative long-term abdominal drains versus repeated drainage in individuals with untreatable ascites due to advanced cirrhosis: study protocol for a feasibility randomised controlled trial. <i>Trials</i> , 2018, 19, 401.	0.7	10

#	ARTICLE	IF	CITATIONS
412	Current and emerging pharmacotherapy for the treatment of bacterial peritonitis. Expert Opinion on Pharmacotherapy, 2018, 19, 1317-1325.	0.9	9
413	Hemodynamic Evaluation of Nonselective $\beta$ -Blockers in Patients with Cirrhosis and Refractory Ascites. Gastroenterology Research and Practice, 2018, 2018, 1-7.	0.7	5
414	Ascites and Spontaneous Bacterial Peritonitis. , 2018, , 182-196.		0
415	Evaluation of postoperative ascites after somatostatin infusion following hepatectomy for hepatocellular carcinoma by laparotomy: a multicenter randomized double-blind controlled trial (SOMAPROTECT). BMC Cancer, 2018, 18, 844.	1.1	5
416	Acute Variceal Bleeding Causes Significant Morbidity. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67, 371-376.	0.9	20
418	Surveillance for portal hypertension in the course of liver cirrhosis. Clinical and Experimental Hepatology, 2018, 4, 49-54.	0.6	2
419	Respiratory Complications Before and After Liver Transplant. Journal of Intensive Care Medicine, 2019, 34, 355-363.	1.3	8
420	Refractory Ascites in Liver Cirrhosis. American Journal of Gastroenterology, 2019, 114, 40-47.	0.2	46
421	Early cirrhosis and a preserved bone marrow niche favour regenerative response to growth factors in decompensated cirrhosis. Liver International, 2019, 39, 115-126.	1.9	21
422	Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation. JHEP Reports, 2019, 1, 270-277.	2.6	12
423	Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan. Internal Medicine, 2019, 58, 3069-3075.	0.3	4
424	The first Chinese guidelines on the Management of Ascites and its Related Complications in Cirrhosis: a great goal for a great country. Hepatology International, 2019, 13, 395-398.	1.9	1
425	The impact of carbapenemase-producing Enterobacteriaceae colonization on infection risk after liver transplantation: a prospective observational cohort study. Clinical Microbiology and Infection, 2019, 25, 1525-1531.	2.8	34
426	Ascites and Hepatorenal Syndrome. Clinics in Liver Disease, 2019, 23, 659-682.	1.0	20
427	Effects of gadoxetic acid on image quality of arterial multiphase magnetic resonance imaging of liver: comparison study with gadoteric acid-enhanced MRI. Abdominal Radiology, 2019, 44, 4037-4047.	1.0	4
428	IL-22 and IL-22-Binding Protein Are Associated With Development of and Mortality From Acute and Chronic Liver Failure. Hepatology Communications, 2019, 3, 392-405.	2.0	33
429	Omega-3 and -6 fatty acid plasma levels are not associated with liver cirrhosis-associated systemic inflammation. PLoS ONE, 2019, 14, e0211537.	1.1	9
430	The predictive value of future liver remnant function after liver resection for HCC in noncirrhotic and cirrhotic patients. Hpb, 2019, 21, 912-922.	0.1	26

#	ARTICLE	IF	CITATIONS
431	Current and future pharmacological therapies for managing cirrhosis and its complications. <i>World Journal of Gastroenterology</i> , 2019, 25, 888-908.	1.4	36
432	Six-minute walk test before and after large-volume paracentesis in cirrhotic patients with refractory ascites: A pilot study. <i>Arab Journal of Gastroenterology</i> , 2019, 20, 81-85.	0.4	7
433	Hepatic Hydrothorax: An Updated Review on a Challenging Disease. <i>Lung</i> , 2019, 197, 399-405.	1.4	21
434	Patient Selection in Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Refractory Ascites and Associated Conditions. <i>Current Hepatology Reports</i> , 2019, 18, 197-205.	0.4	5
435	Permanent indwelling peritoneal catheters for palliation of refractory ascites in end-stage liver disease: A systematic review. <i>Liver International</i> , 2019, 39, 1594-1607.	1.9	25
436	Outcome of a First Episode of Bacterial Infection in Candidates for Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 1187-1197.	1.3	5
437	Serial assessment of hepatic encephalopathy in patients hospitalised for acute decompensation of cirrhosis. <i>Annals of Hepatology</i> , 2019, 18, 331-337.	0.6	5
438	Study protocol for a randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE trial). <i>BMJ Open Gastroenterology</i> , 2019, 6, e000290.	1.1	13
439	Impact of spider nevus and subcutaneous collateral vessel of chest/abdominal wall on outcomes of liver cirrhosis. <i>Archives of Medical Science</i> , 2019, 15, 434-448.	0.4	12
440	Neutrophil-to-lymphocyte ratio is a predictor of early graft dysfunction following living donor liver transplantation. <i>Liver International</i> , 2019, 39, 1545-1556.	1.9	20
442	Efficacy and safety of umbilical therapy with the traditional Chinese medicine formulation Lishui Xiaogu cataplasm for cirrhotic ascites: protocol for a randomized controlled trial. <i>Trials</i> , 2019, 20, 127.	0.7	4
444	Acupuncture for chronic hepatitis B. <i>The Cochrane Library</i> , 2019, 8, CD013107.	1.5	5
445	Role of Interventional Radiology in Complications of Portal Hypertension. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 342-349.	1.1	4
446	Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis. <i>The Cochrane Library</i> , 2019, 6, CD004039.	1.5	13
447	Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. <i>Liver International</i> , 2019, 39, 98-105.	1.9	100
448	Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 345-351.	0.8	15
449	An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 293-305.	1.4	25
450	Clinical Outcomes of Portosystemic Shunts on the Outcome of Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 693-701.	1.3	13



#	ARTICLE	IF	CITATIONS
451	Effects of hydrochlorothiazide on drainage volume and seroma formation in deep inferior epigastric perforator flap breast reconstruction: Randomized controlled trial. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2020, 73, 663-672.	0.5	5
452	Is It Feasible to Standardize a Composite Postoperative Complication Reporting System for Liver Resection?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2748-2755.	0.9	7
453	Effect of alpha agonists on the prevention of postparacentesis circulatory dysfunction in patients with refractory or recurrent ascites: a meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 303-311.	0.8	1
454	Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1229-1237.	1.4	13
455	Ascitis. <i>Medicine</i> , 2020, 13, 327-337.	0.0	0
456	Correlation of Serum Cardiac Markers with Acute Decompensating Events in Liver Cirrhosis. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-15.	0.7	3
457	Laparoscopic Liver Resection for Hepatocellular Carcinoma in Childâ€Pugh A Patients With and Without Portal Hypertension: A Multicentre Study. <i>World Journal of Surgery</i> , 2020, 44, 3915-3922.	0.8	14
458	Spontaneous Bacterial Peritonitis and Secondary Bacterial Peritonitisâ€a Comprehensive Review. <i>Current Hepatology Reports</i> , 2020, 19, 486-498.	0.4	0
459	Difficult-to-treat ascitic fluid infection is a predictor of transplant-free survival in childhood decompensated chronic liver disease. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 465-472.	0.7	3
460	Prognostic Role of Bacterial and Fungal Infections in Patients With Liver Cirrhosis With and Without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa453.	0.4	7
461	Liverâ€specific scores as predictors of mortality in spontaneous bacterial peritonitis. <i>GastroHep</i> , 2020, 2, 224-231.	0.3	8
462	Spontaneous portosystemic shunts in cirrhosis: Detection, implications, and clinical associations. <i>Digestive and Liver Disease</i> , 2021, 53, 1468-1475.	0.4	12
463	Portal Hypertensive Ascites: Current Status. <i>Current Hepatology Reports</i> , 2020, 19, 226-234.	0.4	1
464	Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-7.	0.8	9
465	Future liver remnant function as a predictor of postoperative morbidity following liver resection for hepatocellular carcinoma â€A risk factor analysis. <i>Surgical Oncology</i> , 2020, 33, 257-265.	0.8	9
466	Albumin: Indications in chronic liver disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 528-535.	1.6	9
467	Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 1, CD013123.	1.5	11
468	Outcomes and Mortality of Grade 1 Ascites and Recurrent Ascites in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 358-366.e8.	2.4	16

#	ARTICLE	IF	CITATIONS
469	A Stepwise Evaluation of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure to Optimize the Indication for Urgent Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2021, 66, 284-295.	1.1	7
470	Magnetic resonance parametric mapping of the spleen for non-invasive assessment of portal hypertension. <i>European Radiology</i> , 2021, 31, 85-93.	2.3	12
471	Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study). <i>Journal of Nephrology</i> , 2021, 34, 77-88.	0.9	8
472	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <i>Journal of Hepatology</i> , 2021, 74, 819-828.	1.8	96
473	Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension. <i>JHEP Reports</i> , 2021, 3, 100190.	2.6	28
474	Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature. <i>Hepatology Communications</i> , 2021, 5, 309-322.	2.0	13
475	Permanent end-colostomy parastomal hernia prevention using a novel three-dimensional mesh. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2021, 25, 655-663.	0.9	3
476	ERCP plus endoscopic ultrasound-guided biliary drainage versus percutaneous transhepatic biliary drainage for malignant hilar biliary obstruction: a multicenter observational open-label study. <i>Endoscopy</i> , 2021, 53, 55-62.	1.0	35
477	Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020. <i>United European Gastroenterology Journal</i> , 2021, 9, 203-208.	1.6	17
478	Measuring soil bulk density from shear wave velocity using piezoelectric sensors. <i>Soil Research</i> , 2021, 59, 107.	0.6	2
480	Oncological Outcomes after Liver Venous Deprivation for Colorectal Liver Metastases: A Single Center Experience. <i>Cancers</i> , 2021, 13, 200.	1.7	10
481	Cohort profile: a multicentre prospective validation cohort of the Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study. <i>BMJ Open</i> , 2021, 11, e037793.	0.8	20
482	Real-world hospital mortality of liver cirrhosis inpatients in Japan: a large-scale cohort study using a medical claims database. <i>Hepatology Research</i> , 2021, 51, 682-693.	1.8	8
483	Liver surgery-specific complications are an independent factor influencing long-term survival following major hepatectomy. <i>Hpb</i> , 2021, 23, 1496-1505.	0.1	3
484	The role of prophylactic antibiotics in hepatitis B virus-related acute-on-chronic liver failure patients at risk of bacterial infection: a retrospective study. <i>Infectious Diseases of Poverty</i> , 2021, 10, 44.	1.5	2
485	Management of Refractory Ascites Due to Portal Hypertension: Current Status. <i>Radiology</i> , 2021, 298, 493-504.	3.6	7
486	Subjective global nutritional assessment as a nutritional tool in childhood chronic liver disease. <i>British Journal of Nutrition</i> , 2022, 127, 904-913.	1.2	2
487	Risk Stratification Score to Predict Readmission of Patients With Acute Decompensated Cirrhosis Within 90 Days. <i>Frontiers in Medicine</i> , 2021, 8, 646875.	1.2	2

#	ARTICLE	IF	CITATIONS
488	ACR Appropriateness Criteria® Radiologic Management of Portal Hypertension. <i>Journal of the American College of Radiology</i> , 2021, 18, S153-S173.	0.9	4
489	A Telemonitoring Intervention for Cirrhotic Ascites Management Is Cost-Saving. <i>Digestive Diseases and Sciences</i> , 2022, 67, 854-862.	1.1	11
490	Intra-abdominal hypertension and abdominal compartment syndrome in the critically ill liver cirrhotic patient—prevalence and clinical outcomes. A multicentric retrospective cohort study in intensive care. <i>PLoS ONE</i> , 2021, 16, e0251498.	1.1	10
491	Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021, 74, 1014-1048.	3.6	311
492	Spontaneous Umbilical Hernia Rupture Associated With Omentum Evisceration in a Patient With Advanced Hepatic Cirrhosis and Refractory Ascites. <i>Cureus</i> , 2021, 13, e16042.	0.2	2
493	Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. <i>JHEP Reports</i> , 2021, 3, 100264.	2.6	35
494	Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study. <i>BMJ Open</i> , 2021, 11, e043083.	0.8	8
495	Different Effects of Total Bilirubin on 90-Day Mortality in Hospitalized Patients With Cirrhosis and Advanced Fibrosis: A Quantitative Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 704452.	1.2	6
496	Clinical Presentation and Management of Endometriosis-Related Hemorrhagic Ascites: A Case Report and Systematic Review of the Literature. <i>Cureus</i> , 2021, 13, e15828.	0.2	1
497	Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. <i>New England Journal of Medicine</i> , 2021, 384, e90.	13.9	1
498	Preventive and Treatment Interventions for Abdominal Ascites of Patients with Liver Cirrhosis: A Systematic Review of Randomized Controlled Trials. <i>Florence Nightingale Journal of Nursing</i> , 2021, 29, 250-262.	0.3	1
499	Sociodemographic characteristics, complications requiring hospital admission and causes of in-hospital death in patients with liver cirrhosis admitted at a district hospital in Ghana. <i>PLoS ONE</i> , 2021, 16, e0253759.	1.1	6
500	Puncture needle with a hard plastic sheath and plastic wings minimizes repuncture attempts in ultrasound-guided paracentesis: a retrospective case-control study. <i>Yeungnam University Journal of Medicine</i> , 2022, 39, 18-23.	0.7	0
501	Brief Review of Portal Hypertension Related Complications. , 0, , .		0
502	Vasoactive drugs for adults with cirrhosis and large ascites treated with paracentesis. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
503	Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis. <i>World Journal of Surgical Oncology</i> , 2021, 19, 200.	0.8	4
504	Management of the major complications of cirrhosis: Beyond guidelines. <i>Journal of Hepatology</i> , 2021, 75, S135-S146.	1.8	20
505	Role of Serum Ascites Albumin Gradient (SAAG) and Portal Vein Congestion Index as Non-Invasive Methods for Prediction of Esophageal Varices in Cirrhotic Patients —. <i>Afro-Egyptian Journal of Infectious and Endemic Diseases</i> , 2021, .	0.1	0

#	ARTICLE	IF	CITATIONS
506	Incidence of spontaneous bacterial peritonitis among asymptomatic cirrhosis patients undergoing outpatient paracentesis: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e851-e857.	0.8	9
507	Tuberculosis in Cirrhosis – A Diagnostic and Management Conundrum. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 278-286.	0.4	8
508	Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2021, 53, 1089-1104.	0.4	10
509	Treatment of refractory ascites with an automated low flow ascites pump in patients awaiting liver transplantation. <i>Journal of Liver Transplantation</i> , 2021, 4, 100037.	0.2	2
510	Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e289-e297.	2.4	17
511	Medical Treatment of Ascites in Cirrhosis. , 0, , 227-240.		6
512	Liver Transplantation for Patients with Cirrhosis and Ascites. , 0, , 271-285.		5
513	Session 3: Prevention of the Formation of Varices (Pre-Primary Prophylaxis). , 0, , 103-151.		3
514	Pathophysiology of Portal Hypertension. , 2015, , 3631-3665.		8
515	Fluid, Electrolyte, and Acid-Base Disturbances in Liver Disease. , 2006, , 437-477.		5
516	Hepatic Physiology and Pathophysiology. , 2010, , 411-440.		6
518	Renal Dysfunction in Cirrhosis: Pathophysiology, Clinical Features and Therapy. , 2006, , 417-452.		1
519	HEPATIC CIRRHOSIS. , 2009, , 505-525.		2
520	Liver Disease. , 2012, , 1637-1693.		4
521	Where does TIPS fit in the management of patients with cirrhosis?. <i>JHEP Reports</i> , 2020, 2, 100122.	2.6	72
523	Microcirculatory changes in the liver of patients with refractory ascites and their relationship with diabetes and alcohol. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	0.8	2
524	Aspiration in injections: should we continue or abandon the practice?. <i>F1000Research</i> , 2014, 3, 157.	0.8	12
525	Clinical Profile and Complications of Paracentesis in Refractory Ascites Patients With Cirrhosis. <i>Gastroenterology Research</i> , 2015, 8, 228-233.	0.4	15

#	ARTICLE	IF	CITATIONS
526	RECOMMENDATIONS FOR INVASIVE PROCEDURES IN PATIENTS WITH DISEASES OF THE LIVER AND BILIARY TRACT: REPORT OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN SOCIETY OF DIGESTIVE ENDOSCOPY (SOBED) AND BRAZILIAN SOCIETY OF INTERVENTIONAL RADIOLOGY AND ENDOVASCULAR SURGERY (SOBRICE). <i>Arquivos De Gastroenterologia</i> , 2019, 56, 213-231.	0.3	3
528	Hepatic resection for hepatocellular carcinoma in the octogenarian: is it justified?. <i>Aging</i> , 2019, 11, 1537-1550.	1.4	9
529	Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients. <i>Oncotarget</i> , 2017, 8, 36707-36715.	0.8	4
530	Polymerase Chain Reaction: A Better Method for Diagnosing Chronic <i>Schistosoma mansoni</i>. <i>Infections. Tropical Medicine and Health</i> , 2015, 43, 205-209.	1.0	6
531	Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 129-135.	0.4	6
532	Clinical use of albumin in hepatology. <i>Blood Transfusion</i> , 2009, 7, 268-77.	0.3	47
533	AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. <i>Blood Transfusion</i> , 2016, 14, 8-22.	0.3	13
534	Optimal management of cirrhotic ascites: A review for internal medicine physicians. <i>Journal of Translational Internal Medicine</i> , 2020, 8, 220-236.	1.0	9
535	Chemical pleurodesis using bleomycin in treatment of patients with transsudative pleural effusion in hepatic failure. <i>Vestnik Khirurgii Imeni I I Grekova</i> , 2017, 176, 52-55.	0.0	4
536	Pharmacoepidemiology of ascites and associated complications in hospitalized patients: descriptive observational study. <i>International Current Pharmaceutical Journal</i> , 2015, 4, 343-346.	0.2	2
537	Various Treatment Modalities in Hepatic Hydrothorax: What Is Safe and Effective?. <i>Yonsei Medical Journal</i> , 2019, 60, 944.	0.9	9
538	Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shunt. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 210-217.	4.5	5
539	Evaluation and management of patients with refractory ascites. <i>World Journal of Gastroenterology</i> , 2009, 15, 67.	1.4	48
540	Progress in treatment of massive ascites and hepatorenal syndrome. <i>World Journal of Gastroenterology</i> , 2006, 12, 516.	1.4	11
541	Prognostic factors in non-malignant and non-cirrhotic patients with portal cavernoma: An 8-year retrospective single-center study. <i>World Journal of Gastroenterology</i> , 2013, 19, 7447.	1.4	11
542	Chronic Liver Failure-Sequential Organ Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome. <i>World Journal of Gastroenterology</i> , 2014, 20, 14934.	1.4	67
543	Tolvaptan regulates aquaporin-2 and fecal water in cirrhotic rats with ascites. <i>World Journal of Gastroenterology</i> , 2016, 22, 3363-3371.	1.4	8
544	Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients. <i>World Journal of Gastroenterology</i> , 2016, 22, 5104.	1.4	18

#	ARTICLE	IF	CITATIONS
545	Modulation of splanchnic circulation: Role in perioperative management of liver transplant patients. <i>World Journal of Gastroenterology</i> , 2016, 22, 1582.	1.4	36
546	Current approaches to the management of patients with cirrhotic ascites. <i>World Journal of Gastroenterology</i> , 2019, 25, 3738-3752.	1.4	20
547	Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update. <i>World Journal of Gastroenterology</i> , 2020, 26, 5561-5596.	1.4	61
548	Outcomes of patients treated with Sengstaken-Blakemore tube for uncontrolled variceal hemorrhage. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 696-704.	0.7	13
549	Abdominal compliance, linearity between abdominal pressure and ascitic fluid volume. <i>Journal of Emergencies, Trauma and Shock</i> , 2011, 4, 194.	0.3	24
550	Ultrasound-guided pleurodesis with doxycycline in patients with hepatic hydrothorax. <i>Egyptian Journal of Bronchology</i> , 2016, 10, 20-25.	0.3	1
551	Hepatorenal Syndrome. <i>International Journal of Clinical Medicine</i> , 2014, 05, 102-110.	0.1	1
552	Transjugular intrahepatic porto-systemic shunt in the elderly: Palliation for complications of portal hypertension. <i>World Journal of Hepatology</i> , 2012, 4, 35.	0.8	10
553	Low incidence of spontaneous bacterial peritonitis in asymptomatic cirrhotic outpatients. <i>World Journal of Hepatology</i> , 2013, 5, 104.	0.8	17
554	Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. <i>World Journal of Hepatology</i> , 2015, 7, 1685.	0.8	26
555	Serum 25-hydroxyvitamin D deficiency and hepatic encephalopathy in chronic liver disease. <i>World Journal of Hepatology</i> , 2017, 9, 510.	0.8	14
556	Liver transplantation in adults: Choosing the appropriate timing. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2012, 3, 49.	0.6	8
557	Effect of a Diet with Unrestricted Sodium on Ascites in Patients with Hepatic Cirrhosis. <i>Gut and Liver</i> , 2012, 6, 355-361.	1.4	34
558	Management of Ascites Due to Gastrointestinal Malignancy. <i>Annals of Saudi Medicine</i> , 2009, 29, 369-377.	0.5	11
559	Albumin-bilirubin score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis: A retrospective study. <i>Turkish Journal of Gastroenterology</i> , 2016, 27, 180-186.	0.4	58
560	Cirrhosis with ascites: Is the presence of hemorrhagic ascites an indicator of poor prognosis?. <i>Turkish Journal of Gastroenterology</i> , 2016, 27, 349-353.	0.4	6
561	Transjugular Intrahepatic Portosystemic Shunt for a Wait List Patient Is Not a Contraindication for Orthotopic Liver Transplant Outcomes. <i>Experimental and Clinical Transplantation</i> , 2013, 11, 426-428.	0.2	6
562	Clinical Features of Refractory Ascites in Outpatients. <i>Clinics</i> , 2017, 72, 405-410.	0.6	4

#	ARTICLE	IF	CITATIONS
563	Refractory ascitesâ€™the contemporary view on pathogenesis and therapy. PeerJ, 2019, 7, e7855.	0.9	4
564	The Incidence of Hypersplenism in Decompensated Liver Cirrhosis of Alcoholic Etiology. British Journal of Medicine and Medical Research, 2016, 18, 1-4.	0.2	1
565	Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function. Digestive and Liver Disease, 2022, 54, 1101-1108.	0.4	12
566	Complications of Liver Disease. , 2022, , 443-486.		1
567	ESPEN guideline on hospital nutrition. Clinical Nutrition, 2021, 40, 5684-5709.	2.3	59
569	Management of Ascites. , 2005, , 301-317.		1
570	Leber und Gallenblase/-wege. , 2005, , 143-183.		0
571	Ascitis. , 2006, , 699-701.		0
574	Albumin use in cirrhotic patients: The case against. Saudi Journal of Gastroenterology, 2007, 13, 204.	0.5	0
575	Medical Management of Bleeding Varices. , 2007, , 1563-1578.		0
577	END-STAGE LIVER DISEASE. , 2008, , 477-490.		0
578	A case of liver cirrhosis with refractory ascites treated by peritoneovenous shunt and entecavir. Acta Hepatologica Japonica, 2008, 49, 426-429.	0.0	0
579	Management of ascites and hepatorenal syndrome. , 2009, , 149-163.		0
580	Leber und Gallenblase/-wege. , 2009, , 171-212.		1
582	Complications of Liver Cirrhosis. , 2010, , 967-1031.		1
584	Denver Peritoneovenous Shunt for Refractory Ascites After Partial Liver Resection Offers Longâ€™Term Survival. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2010, 35, 920-925.	0.0	1
585	Complications of Cirrhosis. , 2010, , 524-533.		0
587	Management of Ascites and Hyponatremia. , 2011, , 411-427.		0

#	ARTICLE	IF	CITATIONS
589	Renal Dysfunction and Pathogenesis and Treatment of Ascites and Hepatorenal Syndrome in Cirrhosis. , 2011, , 102-112.		1
590	Renal Dysfunction in Liver Transplant Candidates: Evaluation, Classification and Management in Contemporary Practice. Journal of Nephrology & Therapeutics, 2012, 01, .	0.1	2
592	Intravenous furosemide and human albumin for treatment of cirrhotic ascites: Useful or harmful?. Ibmossina Journal of Medicine and Biomedical Sciences, 2013, 5, 83.	0.2	0
593	Multidisciplinary Approach to the Management of Portal Hypertension. , 2013, , 1593-1609.		0
594	Pathophysiology of Portal Hypertension. , 2014, , 1-41.		1
595	Comparison of abdominal puncture and diuretics during ascites treatment. Scripta Medica, 2014, 45, 51-55.	0.1	0
596	Diagnosis of spontaneous bacterial peritonitis. The Egyptian Journal of Internal Medicine, 2014, 26, 53-59.	0.3	3
597	Herz-Kreislauf-System. , 2015, , 127-175.		0
598	Cirrhotic Portal Hypertension: New Insights in an Old Syndrome. Saãde E Pesquisa, 2015, 8, 389.	0.0	0
600	Short-Term Outcomes of Liver Resection. , 2016, , 83-94.		0
601	Hepatic Hydrothorax in Patients with Decompensated Cirrhosis in Zagazig University Hospitals: A Cross-sectional and Single Center Study. International Journal of Tropical Disease & Health, 2016, 15, 1-8.	0.1	0
602	Complications de la cirrhose. , 2016, , 753-758.		0
605	Refractory Ascites after Liver Transplantation: A Stepwise Approach to Diagnosis and Treatment. Advanced Research in Gastroenterology & Hepatology, 2016, 2, .	0.1	0
606	Long-Term Administration and Outcomes of Tolvaptan for Hepatic Edema. Journal of Liver, 2017, 06, .	0.3	0
608	A Case of Large, Hemodynamically Significant Abdominal Wall Hematoma Following Paracentesis in a Cirrhotic Patient. Cureus, 2017, 9, e1483.	0.2	1
609	The principles of management of patients with liver cirrhosis complicated by ascites. Klinicheskaia Meditsina, 2017, 95, 789-796.	0.2	3
610	Herz-Kreislauf-System. , 2018, , 145-201.		0
611	Ascites Management. Clinical Gastroenterology, 2018, , 31-40.	0.0	0



#	ARTICLE	IF	CITATIONS
612	Complications de la cirrhose. , 2019, , 762-767.		0
613	Up to date treatment of ascites in liver cirrhosis. Sohag Medical Journal (SMJ), 2019, 23, 107-113.	0.1	0
614	Cirrhotic ascites: A review of pathophysiology and management. Nigerian Journal of Gastroenterology and Hepatology, 2020, 12, 3.	0.2	1
615	Natural history of grade 1 ascites in patients with liver cirrhosis. Annals of Gastroenterology, 2020, 34, 93-103.	0.4	1
616	A Novel Prediction Model for Risk of Acute-on-Chronic Liver Failure in Chronic Hepatitis B Virus-Infected Patients With Flare of Hepatitis. SSRN Electronic Journal, 0, , .	0.4	0
617	Efficacy and Pattern of Antibiotic Usage Among Patients with Cirrhosis and/or Chronic Liver Disease in Telangana, India. Exploratory Research and Hypothesis in Medicine, 2020, 000, 1-6.	0.1	0
618	HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan. Pakistan Journal of Medical Sciences, 2020, 36, 1117-1132.	0.3	1
619	Long-term survival prediction for transjugular intrahepatic portosystemic shunt in severe cirrhotic ascites: assessment of ten prognostic models. European Journal of Gastroenterology and Hepatology, 2021, 33, 1547-1555.	0.8	5
620	Transjugular intrahepatic portosystemic shunt for the treatment of refractory hepatic hydrothorax. Acta Hepatologica Japonica, 2020, 61, 399-409.	0.0	1
621	Obesity and myosteatosis: the two characteristics of dynapenia in patients with cirrhosis. European Journal of Gastroenterology and Hepatology, 2021, 33, e916-e921.	0.8	8
622	Ultrasound-guided transverse abdominis plane and ilioinguinal-iliohypogastric nerve block versus ilioinguinal- iliohypogastric nerve block for inguinal hernia repair in patients with liver cirrhosis. Egyptian Journal of Anaesthesia, 2021, 37, 15-20.	0.2	1
623	Spanish online survey on informed consent for the performance of paracentesis. Do we have it? Do we use it?. Revista Espanola De Enfermedades Digestivas, 2020, 112, 854-859.	0.1	0
624	ACUTE-ON-CHRONIC LIVER FAILURE IS INDEPENDENTLY ASSOCIATED WITH LOWER SURVIVAL IN PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS. Arquivos De Gastroenterologia, 2021, 58, 344-352.	0.3	5
626	Prognostic Value of the Alcoholic Hepatitis Histologic Score in Korean Patients with Biopsy-Proven Alcoholic Hepatitis. Gut and Liver, 2020, 14, 636-643.	1.4	3
627	Albumin administration in patients with decompensated liver cirrhosis: a meta-analytic update. European Journal of Gastroenterology and Hepatology, 2021, 33, 479-486.	0.8	12
628	Transjugular Intrahepatic Portosystemic Shunt (Tips) for the Management of Refractory Ascites in Cirrhosis. , 0, , 251-259.		2
631	5 Human Albumin. Transfusion Medicine and Hemotherapy, 2009, 36, 399-407.	0.7	8
632	Use of (18)F-FDG PET/CT to locate primary malignancies in patients with hepatic cirrhosis and malignant ascites. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 500-4.	0.7	1

#	ARTICLE	IF	CITATIONS
633	Malnutrition in liver cirrhosis:the influence of protein and sodium. Middle East Journal of Digestive Diseases, 2013, 5, 65-75.	0.2	41
634	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. Experimental and Therapeutic Medicine, 2021, 21, 30.	0.8	0
635	Management of Ascites in Patients with Cirrhosis: An Update. Journal of Clinical Medicine, 2021, 10, 5226.	1.0	14
636	Ultrasonography in the diagnosis of complications in patients with portal hypertension. Journal of Medical Ultrasonics (2001), 2022, 49, 347-358.	0.6	1
637	Platelet count/spleen volume ratio has a good predictive value for esophageal varices in patients with hepatitis B liver cirrhosis. PLoS ONE, 2021, 16, e0260774.	1.1	7
638	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. Experimental and Therapeutic Medicine, 2020, 21, 1-1.	0.8	2
640	Comparison of Clinical and Radiologic Findings Between Perforated and Non-Perforated Choledochal Cysts in Children. Korean Journal of Radiology, 2022, 23, 271.	1.5	1
642	Can we predict early renal impairment in pediatric cirrhosis?. Indian Journal of Gastroenterology, 2022, , 1.	0.7	2
643	Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma. PLoS ONE, 2022, 17, e0261619.	1.1	4
644	Economic evaluation of long-term albumin use in cirrhosis patients from the Mexican healthcare system perspective. Annals of Hepatology, 2022, 27, 100673.	0.6	4
645	Older age is associated with increased early mortality after transjugular intrahepatic portosystemic shunt. Annals of Hepatology, 2016, 15, 215-221.	0.6	7
647	Decompensated chronic liver disease: A review of current concepts and management guidelines. Current Medicine Research and Practice, 2022, 12, 26.	0.1	0
648	Herz-Kreislauf-System. , 2022, , 181-246.		0
649	Acute Kidney Injury in Patients with Liver Cirrhosis: Prevalence, Predictors, and In-Hospital Mortality at a District Hospital in Ghana. BioMed Research International, 2022, 2022, 1-9.	0.9	8
650	Peritransplant Renal Dysfunction in Liver Transplant Candidates. Clinics in Liver Disease, 2022, 26, 255-268.	1.0	0
651	Rebalanced hemostasis in liver disease: a misunderstood coagulopathy. Hematology American Society of Hematology Education Program, 2021, 2021, 485-491.	0.9	6
652	Gastric outlet obstruction with ascites: EUS-guided gastro-enterostomy is feasible. Endoscopy International Open, 2021, 09, E1918-E1923.	0.9	11
653	The relationship between portal hypertension and portal hypertensive gastropathy. Scandinavian Journal of Gastroenterology, 2022, 57, 340-344.	0.6	3

#	ARTICLE	IF	CITATIONS
654	TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension. <i>European Radiology</i> , 2022, 32, 6777-6787.	2.3	6
656	Monitoring the Patient Awaiting Transplantation. , 0, , 18-42.		0
657	Ascites, Spontaneous Bacterial Peritonitis, Hyponatraemia and Hepatorenal Failure. , 0, , 61-78.		0
659	Management of liver cirrhosis in patients with hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2013, 2, 34.	0.4	5
660	LVP vs TIPS for Refractory Ascites: Where Do We Stand?. <i>Digestive Disease Interventions</i> , 0, 06, .	0.3	0
661	Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites. <i>Scientific Reports</i> , 2022, 12, 8124.	1.6	3
662	Machine learning-based system for prediction of ascites grades in patients with liver cirrhosis using laboratory and clinical data: design and implementation study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1946-1954.	1.4	6
663	Increased Serum Levels of sCD206 Are Associated with Adverse Prognosis in Patients with HBV-Related Decompensated Cirrhosis. <i>Disease Markers</i> , 2022, 2022, 1-10.	0.6	1
664	Home-based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 529-539.	1.9	5
665	Transient severe motion artifacts on gadoxetic acid-enhanced MRI: risk factor analysis in 2230 patients. <i>European Radiology</i> , 2022, 32, 8629-8638.	2.3	1
666	The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: Recent evolution and open questions. <i>Hepatology</i> , 2023, 77, 640-658.	3.6	21
668	Management of refractory ascites. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 16-32.	4.5	10
669	Fluid management in hospitalized pediatric patients. <i>Nutrition in Clinical Practice</i> , 2022, 37, 1033-1049.	1.1	0
670	Palliative long-term abdominal drains for the management of refractory ascites due to cirrhosis: a consensus document. <i>Frontline Gastroenterology</i> , 2022, 13, e116-e125.	0.9	14
671	How much is too much? Pushing the limits of fluid removal via paracentesis. <i>SAGE Open Medical Case Reports</i> , 2022, 10, 2050313X2211096.	0.2	1
672	Transjugular intrahepatic portosystemic shunt with radioactive seed strand for main portal vein tumor thrombosis with cirrhotic portal hypertension. <i>World Journal of Gastrointestinal Surgery</i> , 2022, 14, 567-579.	0.8	2
673	Efficacy and Safety of Ascites Treatment in Liver Cirrhosis. <i>Safety and Risk of Pharmacotherapy</i> , 2022, 10, 161-175.	0.1	0
674	Ascites post-living donor liver transplantation: risk factors and outcome. <i>Journal of Liver Transplantation</i> , 2022, , 100112.	0.2	0

#	ARTICLE	IF	CITATIONS
675	Reversibility of acute-on-chronic liver failure syndrome in hepatitis B virus-infected patients with and without prior decompensation. <i>Journal of Viral Hepatitis</i> , 2022, 29, 890-898.	1.0	3
676	Liver venous deprivation versus associating liver partition and portal vein ligation for staged hepatectomy for colo-rectal liver metastases: a comparison of early and late kinetic growth rates, and perioperative and oncological outcomes. <i>Surgical Oncology</i> , 2022, 43, 101812.	0.8	7
677	Management of the Adult Patient with Cirrhosis Complicated by Ascites. <i>Critical Care Nursing Clinics of North America</i> , 2022, , .	0.4	1
678	Pneumatosis Intestinalis, Pneumoperitoneum, and Ascites Secondary to Scleroderma: A Case Report. <i>Cureus</i> , 2022, , .	0.2	0
679	Use of endoscopic band ligation alone and in combination with nonselective beta blockers for prevention of variceal bleeding in ascites patients on the liver transplant waiting list. <i>Vestnik Transplantologii I Iskusstvennykh Organov</i> , 2022, 24, 42-50.	0.1	3
680	Effect of probiotics on hemodynamic changes and complications associated with cirrhosis: A pilot randomized controlled trial. <i>World Journal of Hepatology</i> , 2022, 14, 1667-1677.	0.8	4
681	An improved method to assess skeletal muscle mass in patients with liver cirrhosis based on computed tomography images. <i>Hepatology Research</i> , 2022, 52, 937-946.	1.8	4
682	Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS. <i>Hepatology</i> , 2023, 77, 466-475.	3.6	6
683	New Algorithm Rules Out Acute-on-chronic Liver Failure Development within 28 Days from Acute Decompensation of Cirrhosis. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	0
684	Development and validation of the Cirrhotic Ascites Severity model – A patient-reported outcome-based model to predict 1-year mortality. <i>Hepatology Communications</i> , 2022, 6, 3175-3185.	2.0	1
685	MANAGEMENT OF ASCITES IN CIRRHOSIS. <i>Problemy Zdorov'ia I Ākologii</i> , 2012, , 28-35.	0.0	0
686	Efficacy and safety of transjugular intrahepatic portosystemic shunt for the treatment of schistosomiasis-induced portal hypertension: a retrospective case series. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 1090-1097.	0.8	3
687	Albumin administration in patients with cirrhosis: Current role and novel perspectives. <i>World Journal of Gastroenterology</i> , 2022, 28, 4773-4786.	1.4	5
688	Impact of Asymptomatic Superior Mesenteric Vein Thrombosis on the Outcomes of Patients with Liver Cirrhosis. <i>Thrombosis and Haemostasis</i> , 2022, 122, 2019-2029.	1.8	6
689	A Case of a Large Intraabdominal Abscess in a Patient with Cirrhosis Misdiagnosed as Spontaneous Bacterial Peritonitis. <i>Case Reports in Hepatology</i> , 2022, 2022, 1-4.	0.4	0
690	Prevention of Further Decompensation in Patients With Ascites. , 2022, , 549-562.		0
691	Cytotoxic T Cell Expression of Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) in Viral Hepatitis C-Mediated Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12541.	1.8	7
692	Covered transjugular intrahepatic portosystemic stent-shunt vs large volume paracentesis in patients with cirrhosis: A real-world propensity score-matched study. <i>World Journal of Clinical Cases</i> , 2022, 10, 11313-11324.	0.3	0

#	ARTICLE	IF	CITATIONS
693	Liver Venous Deprivation Versus Portal Vein Embolization Before Major Hepatectomy for Colorectal Liver Metastases: A Retrospective Comparison of Short- and Medium-Term Outcomes. <i>Journal of Gastrointestinal Surgery</i> , 2023, 27, 296-305.	0.9	3
694	The efficacy of contrast-enhanced computed tomography on the management of gastroesophageal varices in patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
695	External validation of Chronic Liver Failure-Consortium Acute Decompensation score in the risk stratification of cirrhotic patients hospitalized with acute variceal bleeding. <i>European Journal of Gastroenterology and Hepatology</i> , 2023, 35, 302-312.	0.8	2
696	CLIF-SOFA and CLIF-C scores for the prognostication of acute-on-chronic liver failure and acute decompensation of cirrhosis: A systematic review. <i>World Journal of Hepatology</i> , 0, 14, 2025-2043.	0.8	7
697	Preoperative Assessment and Optimization of Liver Transplant Patient: Ascites and Hydrothorax. , 2023, , 115-126.		1
698	Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis. <i>Hepatology</i> , 2023, 77, 1253-1262.	3.6	3
699	Exploration of sodium homeostasis and pharmacokinetics in bile duct-ligated rats treated by anti-cirrhosis herbal formula plus spironolactone. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
700	Survival outcomes of patients with concomitant acute variceal bleeding and acute coronary syndrome, and the role of antiplatelet agents: an institutional experience from a lower middle-income Country. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
701	Dynamic Prediction of Resectability for Patients with Advanced Ovarian Cancer Undergoing Neo-Adjuvant Chemotherapy: Application of Joint Model for Longitudinal CA-125 Levels. <i>Cancers</i> , 2023, 15, 231.	1.7	1
702	Nonselective beta-blockers in primary prophylaxis of esophageal variceal bleeding in patients with ascites waitlisted for liver transplantation. <i>Vestnik Transplantologii I Iskusstvennykh Organov</i> , 2023, 25, 68-76.	0.1	0
703	Diagnosis and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome. <i>Cleveland Clinic Journal of Medicine</i> , 2023, 90, 209-213.	0.6	2
704	Cirrhosis and Portal Hypertension. <i>Medical Clinics of North America</i> , 2023, 107, 505-516.	1.1	4
705	Paracentesis evacuante en pacientes cirr3ticos con ascitis a tensi3n: revisi3n del tema. <i>Iatreia</i> , 2010, 23, .	0.1	0
706	Proximal Splenic Artery Embolization for Refractory Ascites and Hydrothorax Post-Liver Transplant. <i>CardioVascular and Interventional Radiology</i> , 2023, 46, 470-479.	0.9	1
707	<scp>HBcAb</scp> positivity increases the risk of postoperative complications after extended hemihepatectomy for hilar cholangiocarcinoma. <i>Cancer Medicine</i> , 0, , .	1.3	1
708	First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan. <i>BMJ Open Gastroenterology</i> , 2023, 10, e001120.	1.1	1
711	Complications de la cirrhose. , 2023, , 816-821.		0
712	Ascites and Chronic Liver Disease in Children. <i>Indian Journal of Pediatrics</i> , 2024, 91, 270-279.	0.3	2

#	ARTICLE	IF	CITATIONS
729	What Are the Causes and Complications of Chronic Liver Disease and What Is the Evidence for Palliative Care Delivery to Those Affected by It?. , 2023, , 357-370.		0